Biousian glycopeptides penetrate the blood-brain barrier

Richard D. Egleton, Edward J. Bilsky, Gordon Tollin, Muthu Dhanasekaran, John Lowery, Isabel Alves, Peg Davis, Frank Porreca, Henry I. Yamamura, Larisa Yeomans, Charles M. Keyari, Robin L Polt

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Clinicians have long desired the ability to introduce either exogenous or endogenous neuropeptides directly into the brain in order to alter brain chemistry, but have been thwarted by the blood-brain barrier (BBB). The BBB blocks the introduction of most peptides and proteins into the brain. Glycosylation can be employed as an effective and practical strategy that allows the systemic use of neuropeptides in vivo. A series of glycopeptides based on the Leu-enkephalin analogue YtGFS*-CONH2 led to greatly enhanced stability in vivo and effective penetration of the BBB. Transport through the BBB hinges on the biousian nature of the glycopeptides. That is, the amphipathic glycopeptides possess two conflicting solubility states; one state that is completely water soluble, and another at water-membrane phase boundaries. Multiple lines of evidence suggest that the BBB transport is absorptive endocytosis. Several Leu-enkephalin analogues studied showed antinociceptive potencies greater than morphine. Moreover, these δ-selective glycopeptides lacked many of the μ-opioid side effects generally associated with classical opiate analgesics. The biousian design was extended to much larger glycopeptides (16-17 residues) related to β-endorphin, which also penetrated the BBB and produced antinociception in mice. Plasmon-waveguide resonance (PWR) studies showed that the amphipathic helices bound to membrane bilayers with micromolar to low nanomolar K D's. The presence of diverse endogenous neuropeptide transmitters and neuromodulators in the human brain is potentially applicable to the treatment of a wide range of behavioral disorders.

Original languageEnglish (US)
Pages (from-to)65-75
Number of pages11
JournalTetrahedron Asymmetry
Volume16
Issue number1
DOIs
StatePublished - Jan 10 2005

Fingerprint

blood-brain barrier
Glycopeptides
Blood-Brain Barrier
brain
Brain
Neuropeptides
Leucine Enkephalin
Opiate Alkaloids
Brain Chemistry
morphine
analogs
membranes
Endorphins
Glycosylation
Membranes
Water
hinges
Phase boundaries
Hinges
Endocytosis

ASJC Scopus subject areas

  • Inorganic Chemistry
  • Organic Chemistry
  • Materials Chemistry
  • Drug Discovery

Cite this

Egleton, R. D., Bilsky, E. J., Tollin, G., Dhanasekaran, M., Lowery, J., Alves, I., ... Polt, R. L. (2005). Biousian glycopeptides penetrate the blood-brain barrier. Tetrahedron Asymmetry, 16(1), 65-75. https://doi.org/10.1016/j.tetasy.2004.11.038

Biousian glycopeptides penetrate the blood-brain barrier. / Egleton, Richard D.; Bilsky, Edward J.; Tollin, Gordon; Dhanasekaran, Muthu; Lowery, John; Alves, Isabel; Davis, Peg; Porreca, Frank; Yamamura, Henry I.; Yeomans, Larisa; Keyari, Charles M.; Polt, Robin L.

In: Tetrahedron Asymmetry, Vol. 16, No. 1, 10.01.2005, p. 65-75.

Research output: Contribution to journalArticle

Egleton, RD, Bilsky, EJ, Tollin, G, Dhanasekaran, M, Lowery, J, Alves, I, Davis, P, Porreca, F, Yamamura, HI, Yeomans, L, Keyari, CM & Polt, RL 2005, 'Biousian glycopeptides penetrate the blood-brain barrier', Tetrahedron Asymmetry, vol. 16, no. 1, pp. 65-75. https://doi.org/10.1016/j.tetasy.2004.11.038
Egleton RD, Bilsky EJ, Tollin G, Dhanasekaran M, Lowery J, Alves I et al. Biousian glycopeptides penetrate the blood-brain barrier. Tetrahedron Asymmetry. 2005 Jan 10;16(1):65-75. https://doi.org/10.1016/j.tetasy.2004.11.038
Egleton, Richard D. ; Bilsky, Edward J. ; Tollin, Gordon ; Dhanasekaran, Muthu ; Lowery, John ; Alves, Isabel ; Davis, Peg ; Porreca, Frank ; Yamamura, Henry I. ; Yeomans, Larisa ; Keyari, Charles M. ; Polt, Robin L. / Biousian glycopeptides penetrate the blood-brain barrier. In: Tetrahedron Asymmetry. 2005 ; Vol. 16, No. 1. pp. 65-75.
@article{90e3c79cfdc24d6393a4d38ccdab2879,
title = "Biousian glycopeptides penetrate the blood-brain barrier",
abstract = "Clinicians have long desired the ability to introduce either exogenous or endogenous neuropeptides directly into the brain in order to alter brain chemistry, but have been thwarted by the blood-brain barrier (BBB). The BBB blocks the introduction of most peptides and proteins into the brain. Glycosylation can be employed as an effective and practical strategy that allows the systemic use of neuropeptides in vivo. A series of glycopeptides based on the Leu-enkephalin analogue YtGFS*-CONH2 led to greatly enhanced stability in vivo and effective penetration of the BBB. Transport through the BBB hinges on the biousian nature of the glycopeptides. That is, the amphipathic glycopeptides possess two conflicting solubility states; one state that is completely water soluble, and another at water-membrane phase boundaries. Multiple lines of evidence suggest that the BBB transport is absorptive endocytosis. Several Leu-enkephalin analogues studied showed antinociceptive potencies greater than morphine. Moreover, these δ-selective glycopeptides lacked many of the μ-opioid side effects generally associated with classical opiate analgesics. The biousian design was extended to much larger glycopeptides (16-17 residues) related to β-endorphin, which also penetrated the BBB and produced antinociception in mice. Plasmon-waveguide resonance (PWR) studies showed that the amphipathic helices bound to membrane bilayers with micromolar to low nanomolar K D's. The presence of diverse endogenous neuropeptide transmitters and neuromodulators in the human brain is potentially applicable to the treatment of a wide range of behavioral disorders.",
author = "Egleton, {Richard D.} and Bilsky, {Edward J.} and Gordon Tollin and Muthu Dhanasekaran and John Lowery and Isabel Alves and Peg Davis and Frank Porreca and Yamamura, {Henry I.} and Larisa Yeomans and Keyari, {Charles M.} and Polt, {Robin L}",
year = "2005",
month = "1",
day = "10",
doi = "10.1016/j.tetasy.2004.11.038",
language = "English (US)",
volume = "16",
pages = "65--75",
journal = "Tetrahedron Asymmetry",
issn = "0957-4166",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Biousian glycopeptides penetrate the blood-brain barrier

AU - Egleton, Richard D.

AU - Bilsky, Edward J.

AU - Tollin, Gordon

AU - Dhanasekaran, Muthu

AU - Lowery, John

AU - Alves, Isabel

AU - Davis, Peg

AU - Porreca, Frank

AU - Yamamura, Henry I.

AU - Yeomans, Larisa

AU - Keyari, Charles M.

AU - Polt, Robin L

PY - 2005/1/10

Y1 - 2005/1/10

N2 - Clinicians have long desired the ability to introduce either exogenous or endogenous neuropeptides directly into the brain in order to alter brain chemistry, but have been thwarted by the blood-brain barrier (BBB). The BBB blocks the introduction of most peptides and proteins into the brain. Glycosylation can be employed as an effective and practical strategy that allows the systemic use of neuropeptides in vivo. A series of glycopeptides based on the Leu-enkephalin analogue YtGFS*-CONH2 led to greatly enhanced stability in vivo and effective penetration of the BBB. Transport through the BBB hinges on the biousian nature of the glycopeptides. That is, the amphipathic glycopeptides possess two conflicting solubility states; one state that is completely water soluble, and another at water-membrane phase boundaries. Multiple lines of evidence suggest that the BBB transport is absorptive endocytosis. Several Leu-enkephalin analogues studied showed antinociceptive potencies greater than morphine. Moreover, these δ-selective glycopeptides lacked many of the μ-opioid side effects generally associated with classical opiate analgesics. The biousian design was extended to much larger glycopeptides (16-17 residues) related to β-endorphin, which also penetrated the BBB and produced antinociception in mice. Plasmon-waveguide resonance (PWR) studies showed that the amphipathic helices bound to membrane bilayers with micromolar to low nanomolar K D's. The presence of diverse endogenous neuropeptide transmitters and neuromodulators in the human brain is potentially applicable to the treatment of a wide range of behavioral disorders.

AB - Clinicians have long desired the ability to introduce either exogenous or endogenous neuropeptides directly into the brain in order to alter brain chemistry, but have been thwarted by the blood-brain barrier (BBB). The BBB blocks the introduction of most peptides and proteins into the brain. Glycosylation can be employed as an effective and practical strategy that allows the systemic use of neuropeptides in vivo. A series of glycopeptides based on the Leu-enkephalin analogue YtGFS*-CONH2 led to greatly enhanced stability in vivo and effective penetration of the BBB. Transport through the BBB hinges on the biousian nature of the glycopeptides. That is, the amphipathic glycopeptides possess two conflicting solubility states; one state that is completely water soluble, and another at water-membrane phase boundaries. Multiple lines of evidence suggest that the BBB transport is absorptive endocytosis. Several Leu-enkephalin analogues studied showed antinociceptive potencies greater than morphine. Moreover, these δ-selective glycopeptides lacked many of the μ-opioid side effects generally associated with classical opiate analgesics. The biousian design was extended to much larger glycopeptides (16-17 residues) related to β-endorphin, which also penetrated the BBB and produced antinociception in mice. Plasmon-waveguide resonance (PWR) studies showed that the amphipathic helices bound to membrane bilayers with micromolar to low nanomolar K D's. The presence of diverse endogenous neuropeptide transmitters and neuromodulators in the human brain is potentially applicable to the treatment of a wide range of behavioral disorders.

UR - http://www.scopus.com/inward/record.url?scp=19944434130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944434130&partnerID=8YFLogxK

U2 - 10.1016/j.tetasy.2004.11.038

DO - 10.1016/j.tetasy.2004.11.038

M3 - Article

AN - SCOPUS:19944434130

VL - 16

SP - 65

EP - 75

JO - Tetrahedron Asymmetry

JF - Tetrahedron Asymmetry

SN - 0957-4166

IS - 1

ER -